A Comparative Study of the Therapeutic Effect of Probucol and Pravastatin on Xanthelasma
- 1 September 1996
- journal article
- clinical trial
- Published by Wiley in The Journal of Dermatology
- Vol. 23 (9), 598-602
- https://doi.org/10.1111/j.1346-8138.1996.tb02661.x
Abstract
We examined and compared the effects of probucol and pravastatin on the regression of xanthelasma. Thirty-six cases treated by probucol and 18 cases by pravastatin were evaluated for 12 months. Thirteen of the 36 cases treated with probucol showed regression of xanthelasma. However, one of the 18 cases treated with pravastatin showed regression. These data were statistically significantly. The average total cholesterol value in both groups decreased during drug therapy. However, the average of HDL-cholesterol values in the probucol treatment group showed significant decreases, but those in the pravastatin treatment group did not. We discussed the mechanisms of the two drugs on the regression of xanthelasma and the mechanisms of development of xanthelasma.Keywords
This publication has 6 references indexed in Scilit:
- Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transferThe American Journal of Cardiology, 1988
- Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbitsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988
- Effects of probucol on xanthomata regression in familial hypercholesterolemiaThe American Journal of Cardiology, 1986
- Effects of probucol on homozygous cases of familial hypercholesterolemiaAtherosclerosis, 1983
- Effects of Long-Term Probucol Treatment on Serum Lipids, Lipoprotein Lipids and Skin Xanthomas in Heterozygous Familial Hypercholesterolemic PatientsThe Journal of Japan Atherosclerosis Society, 1983
- Long‐Term Oral Administration of Probucol [4, 4‘‐(Isopropylidenedithio) bis (2, 6‐di‐t‐Butylphenol)] (DH‐581) in the Management of Hypercholesterolemia*Journal of the American Geriatrics Society, 1974